For the second time in 16 months, Massachusetts biotech Agenus is reorganizing after failing to gain traction with the FDA on its PD-1 candidate balstilimab. Last week, the immuno-oncology specialist ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of ...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November ...
Agenus will be reporting earnings from the last quarter on August 8. Wall Street analysts are expecting losses per share of $1.066. Go here to watch Agenus stock price in real-time on Markets Insider.
Effective January 8, 2026, Agenus Inc.’s board appointed Chairman and Chief Executive Officer Dr. Garo Armen as interim Chief Financial Officer and Principal Financial Officer, consolidating key ...
In a regulatory filing and a letter to its shareholders, both published Thursday, Agenus revealed that it is seeking a reverse stock split. The proposed ratio is one share of the biotech company's ...
Agenus Inc. (NASDAQ:AGEN) shares are trading higher Tuesday after the company announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and ...
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations ...
Agenus Inc. has unveiled promising data from the NEST-1 study, showing the potential of the combination of botensilimab and balstilimab in colorectal cancer treatment. The combination demonstrated ...
Botensilimab (AGEN1181) is a next-generation, multifunctional, Fc-enhanced CTLA-4 antibody engineered to boost both innate and adaptive anti-tumor immune responses. Its unique design aims to overcome ...
Agenus (AGEN) shares ended the last trading session 19.3% higher at $7.06. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results